Setidegrasib

N/A

Report date: 2026/05/06 20:02:28
NMEFirst In Class

Base Information

Drug NameSetidegrasib
Drug Alias NameASP-3082
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionKRAS G12D degraders
TargetsKRAS G12D
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoFrance +[7] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAstellas Pharma Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAstellas (China) Investment Co LtdAstellas Pharma IncAstellas Pharma Global Development Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisCarcinoma, Non-Small-Cell Lung +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A